Transcutaneous Stimulation in Spinal Cord Injury (SCI)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Cardiovascular disease has become the leading cause of death in the spinal cord injury population. Increased reliance on the renin-angiotensin-aldosterone system (RAAS) is believed to decrease falls in blood pressure when moving from a laying down position to upright; however, findings in the general population link the RAAS with remodeling and restructuring of the arterial walls. Therefore, intervention to stabilize and normalize blood pressure should be a priority in individuals with spinal cord injury who have low blood pressure. Advances in stimulation on the skin of the spinal cord offer an approach to restore cardiovascular control and improve blood pressure regulation; however, electrode placement and stimulation parameters needed to increase blood pressure are not well understood. Therefore, the aim of the study is to identify placement of electrodes on the skin, and frequency and amplitude of the stimulation to regulate blood pressure.
Full description
Although life expectancies have improved in the SCI population, longevity remains below the general population, due to increased incidence of cardiovascular disease, which is the leading cause of mortality in individuals with chronic SCI. Autonomic nervous system dysfunction and blood pressure instability contribute to the increased cardiovascular disease risk in the SCI population; however, because a majority of individuals with SCI remain asymptomatic the diagnosis and treatment of blood pressure instability is not a clinical priority. This is due, in part, to lack of safe and effective interventions, even though mounting evidence strongly supports adverse effects of blood pressure instability on the cerebral circulation, cognitive function, and quality of life. Identifying individualized transcutaneous stimulation parameters that safely and effectively increase and stabilize blood pressure in hypotensive individuals with SCI will provide the foundational evidence to support eventual wide-spread clinical utility throughout the VA healthcare system. 10 participants who are cleared, will go through multiple mapping sessions to find out the most appropriate electrode placement to increase seated blood pressure. The study will take approximately 1 to 13 study visits, of between 3-5 hours, per participant.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
-
above the age of 18 years old
-
individuals with traumatic spinal cord injuries at or above T6
- duration of injury if more than 1 year
- non-ambulatory
- American spinal injury association scale A, B or C
-
able to provide consent
-
non-ventilator
-
hypotensive (males: systolic blood pressure less than 110 mmHg and/or diastolic blood pressure less than 70 mmHg; females: systolic blood pressure less than 100 mmHg and/or diastolic blood pressure less than 70 mmHg)
Exclusion criteria
- acute illness or infection
- documented history of controlled or uncontrolled diabetes
- any other neurological disease other than spinal cord injury
- cardiovascular disease (coronary artery disease, congestive heart failure, peripheral artery disease, stroke)
- present of history of thrombosis in the last 12 months, severe contractures
- pregnant
Trial design
Primary purpose
Allocation
Interventional model
Masking
10 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Caitlyn Peters, PhD; Jill Wecht, EdD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal